A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-beta2GPI / anti-beta2-glycoprotein I

[Related PubMed/MEDLINE]
Total Number of Papers: 141
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-beta2GPI  (>> Co-occurring Abbreviation)
Long Form:   anti-beta2-glycoprotein I
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2022 Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. aPL, APS, CVD, ox-LDL, SLE
2  2021 Association of antiphospholipid antibodies with clinical activity and renal pathological activity in patients with lupus nephritis. aPL, LAC, LN
3  2021 Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. AT, LA, SLE, VTE
4  2021 Characteristics of purified anti-β2GPI IgG N-glycosylation associate with thrombotic, obstetric and catastrophic antiphospholipid syndrome. aPLs, APS, CAPS, HC, MRM
5  2021 Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome. anti-CL, CI, IgG, IgM, ISTH, LAC, OR
6  2021 Imbalance of circulating CTLA4+ follicular helper and follicular regulatory T cells in obstetric antiphospholipid syndrome. aPL, aPLs, CTLA-4, OAPS
7  2021 Longitudinal Analysis of Anti-cardiolipin and Anti-beta2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. aCL, aPL, APS, SLE
8  2021 Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis. aCL, AIS, aPLs, LA, LETM, SLE, SLEDAI, TM
9  2021 The correlation of anti-beta2-glycoprotein I antibody with complement activation in patients with idiopathic membranous nephropathy. IMN, PLA2R
10  2021 The Diagnostic Value of New Additional Antiphospholipid Antibodies in Antiphospholipid Syndrome. aAA5, aCL, aPL, APS, aPS, aPT, ELISA, LA
11  2021 The Predictive Value of the aCL and Anti-beta2GPI at the Time of Acute Deep Vein Thrombosis-A Two-Year Prospective Study. aCL, APS, DVT, LA
12  2020 Anti-beta2-glycoprotein I autoantibodies influence thrombin generation parameters via various mechanisms. aPL, APS
13  2020 Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. aCL, aPL, APTT, COVID-19
14  2020 Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. aCL, aPLs, APTT, COVID-19
15  2020 Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis. aCL, aPLs, LAC, LN
16  2020 Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. aCL, aPL, LAC
17  2020 Beta-2-glycoprotein-I IgA antibodies predict coronary plaque progression in rheumatoid arthritis. CAC, CVD, RA
18  2020 Clinical performance of automated chemiluminescent methods for anticardiolipin and anti-beta2-glycoprotein I antibodies detection in a large cohort of Chinese patients with antiphospholipid syndrome. aCL, aPL, APS, AUC, CIA, ELISA
19  2020 Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-beta2 glycoprotein I domain 1 antibodies. anti-CCP2, anti-CL, anti-TPO, aPL, RF
20  2020 What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome? aCL, aPL, APS, EMA, LA, MHRA
21  2019 Amniotic fluid antiphospholipid antibodies: potential role in antiphospholipid syndrome-independent aberrant implantation process. AF, AHT, aPL, APS, PL Ags, RPL
22  2019 Anti-beta2GPI/beta2GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies. MAPK
23  2019 Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients. aCL, anti-D1, APOs, CI, LA, OR, TE
24  2019 Antiphospholipid Antibodies in Patients with Membranous Nephropathy. FSGS, MCD, MN
25  2019 Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events? DI, VE
26  2019 Association between antiphospholipid antibodies and factor Bb in lupus nephritis patients with glomerular microthrombosis. aCLs, aPLs, GMT, LAC, LN
27  2019 Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. aCL, SLE
28  2019 B cell-derived anti-beta 2 glycoprotein I antibody contributes to hyperhomocysteinaemia-aggravated abdominal aortic aneurysm. AAAs, Hcy, HHcy, TLR4
29  2019 Comparison of Clinical and Hematologic Factors Associated with Stenosis and Aneurysm Development in Patients with Atherosclerotic Arterial Disease. Ig
30  2019 Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. APS, CAPS, mHam, SLE
31  2019 Differential CpG methylation of the promoter of interleukin 8 and the first intron of tissue factor in Antiphospholipid syndrome. APS, HDs, HUVECs, IL-6
32  2019 Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy. aCL, aPL, MDT
33  2019 Laboratory Evaluation of Antiphospholipid Syndrome. APS, LAC
34  2019 Mitigating placental injuries through up-regulating DAF in experimental APS mice: new mechanism of progesterone. aPL, APS, CIPs
35  2018 Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. aCL, aPLs, CIs, NOS, OR, ORs
36  2018 Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. aCL, ACR, anti-Rib-P, CI, CNS, DS, ERPs, NP, SLE, SLEDAI, VFT
37  2018 Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis. aCL, APLAs, aPTT-LA, EVs, IQR, LA, TF
38  2018 Multiple Arterial Thrombosis Related with Cantharidin Ingestion. ---
39  2018 Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. aCL, anti-PI, anti-PS, APhL, aPL, ELISAs, IgG, IgM
40  2018 Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis. aCL, aPL, LA, SSc, VT
41  2018 Prevalence of Antiphospholipid Antibody Positivity and Association of Pretransplant Lupus Anticoagulant Positivity With Early Allograft Dysfunction in Liver Transplantation. aCL, aPL, EAD, IPTW, LA, LDLT
42  2017 Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. aCL, APS, AS, LAC, OR, RA, SLE, SN-APS, SS
43  2017 Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis. aCL, CIs, LA, ORs
44  2017 Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. aCL, aPL, CI, EBV, HBV, HCV, HIV, RR
45  2017 The Clinical Relevance of Noncriteria Antiphospholipid Antibodies. aCL, aPL, APS, LA
46  2016 A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. aCL, aPL, APS, SLE
47  2016 Antiphospholipid syndrome with subsequent chronic discoid lupus erythematosus: a case report. aCL, LAC, SLE
48  2016 Clinical significance and correlations between anti-beta2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. aPL, APS, SLE
49  2016 Detection of lupus anticoagulant in the era of direct oral anticoagulants. aCL, DOACs, LAC
50  2016 Effects of Anti-beta2-Glycoprotein I Antibody on the Expression of Toll-like Receptors mRNA in Choriocarcinoma and Primary Trophoblast Cells. TLR
51  2016 Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study. aCL, aPL, APS, APTT, AUC, SLE
52  2016 Identification of patients with triple antiphospholipid antibody positivity is platform and method independent. aPL, APS
53  2016 Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. HCQ, PAPS
54  2015 A contribution to detection of anticardiolipin and anti-beta2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. aCL, aPL, FEIA, PAPS
55  2015 Anti-beta2 glycoprotein I antibodies in complex with beta2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2' and glycoprotein I balpha. APS, GP I ba
56  2015 Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. aPL, aPS, HR, TOEs
57  2015 Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4. aPL, APS, LPS, TF, TLR4
58  2015 Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of literature studies. aCL, AIH, AILD, aPL, LA, PBC, PSC
59  2015 Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. aCL, aPL, APS, Ig, LA
60  2015 The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-beta2 glycoprotein I antibodies. A comparison with a homemade ELISA method. aCL, APS, CLIAs, ELISA
61  2014 A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes. AFM, aPL, APS, HCQ, Ig
62  2014 Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. APS, NHS
63  2014 IgA anticardiolipin and IgA anti-beta2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. aCL, aPL, FEIA, LA, PAPS
64  2014 International standards for IgG and IgM anti-beta2glycoprotein antibody measurement. AP, RM
65  2014 Isolated anti-beta2-glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome? APS
66  2014 Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? aCL, anti-dsDNA, aPL, ELISA, PAPS
67  2014 Selective adsorption of antiphospholipid and anti-dsDNA autoantibodies on histidine based pseudobioaffinity adsorbent from sera of patients with systemic lupus erythematosus (SLE). aCL, anti-dsDNA, SLE
68  2014 The beneficial effect of plasmapheresis in mixed connective tissue disease with coexisting antiphospholipid syndrome. anti-CL, APS, EBV, MCTD
69  2014 Triple positive antiphospholipid antibody profile in outpatients with tests for lupus anticoagulants. aCL, aPL, dRVVT, LAC, SCT
70  2013 Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. aCL, APA, CAC, CARDIA, Ig
71  2013 Hemodialysis duration, human platelet antigen HPA-3 and IgA isotype of anti-beta2glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients. AVF
72  2013 Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. aPL, APS, P-sel, TRAP-6
73  2013 Prevalence of antiphospholipid antibodies in patients with subacute and chronic cutaneous lupus erythematosus. ACAs, ANAs, APLAs, APS, CLE, LA, SLE
74  2012 Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. aCL, AIRD, ANA, anti-ENA, ASIA
75  2012 Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. aCL, aPE, aPL, APS, aPT, LA, SLE, YI
76  2012 Clinical and laboratory characteristics of children positive for antiphospholipid antibodies. aCL, aPL, APS, LA
77  2012 European registry of babies born to mothers with antiphospholipid syndrome. aCL, aPL, SLE
78  2012 The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. aCL, ANCA, BPI, MPO, PR3, TB
79  2011 Anti-beta2-glycoprotein I antibodies are highly prevalent in a large number of Brazilian leprosy patients. aCL, aPL, APS, MDT
80  2011 Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. aCL, ANA, CIS, ENA, MS, SPMS
81  2011 Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. aCL, aPL, CRP, LA, RVSP, SLE, SPECT
82  2011 Effects of anti-beta2-glycoprotein I antibody on PlGF, VEGF and sVEGFR1 production from cultured choriocarcinoma cell line. IgG, PlGF, sVEGFR-1, VEGF
83  2011 [Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage]. APS, LA, RM
84  2010 Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden. FVL, SGA
85  2010 Rational Laboratory Diagnostics of Antiphospholipid Antibodies: Anti-Cardiolipin, Anti-beta2-Glycoprotein I, Anti-Prothrombin and Anti-Annexin V Antibodies. aANX V, aCL, aPL, aPT
86  2010 Standardized antigen preparation to achieve comparability of anti-beta2-glycoprotein I assays. APS, SPR
87  2010 [Clinical value of antibodies to lysobisphosphatidic acid in patients with primary antiphospholipid syndrome]. aCL, anti-LBPA, APS, LA
88  2009 Accuracy of the first fully automated method for anti-cardiolipin and anti-beta2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome. aCL, APS
89  2009 Annexin A2 mediates anti-beta 2 GPI/beta 2 GPI-induced tissue factor expression on monocytes. ANX2, APS, TF
90  2009 Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. ACAs, aCL, OR, PAH
91  2009 Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Ig
92  2008 A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. aCL, aPL, LA
93  2008 A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is? aCL, APS, ELISA, LA
94  2008 Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation. aCL, aPL, APS, LA, TF
95  2008 Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? aCL, APS
96  2008 Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. APS, P38 MAPK
97  2008 [Antiphospholipid antibodies in patients with coronary heart disease and the disturbances of glucose tolerance]. aPL, aPS
98  2007 Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. aCL, ANA, aPL, MI
99  2007 Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. ---
100  2007 Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. anti-P, ELISA, NP, SLE, SLEDAI